BiogenedWAR:BGD 68 Market Cap is zł45.0 Mil as of Jul. 08, 2026. GuruFocus rates WAR:BGD with a GF Score™ of 68/100 and a GF Value™ of zł23.85 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,024 Drug Manufacturers companies, Biogened ranks worse than 84.18% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Biogened's share price for the quarter that ended in Mar. 2026 was zł17.8. Biogened's Shares Outstanding (EOP) for the quarter that ended in Mar. 2026 was 2.5 Mil. Therefore, Biogened's market cap for the quarter that ended in Mar. 2026 was zł43.7 Mil.
Biogened's quarterly market cap
declined
from Sep. 2025 (zł58.9 Mil) to Dec. 2025 (zł53.0 Mil) and
declined
from Dec. 2025 (zł53.0 Mil) to Mar. 2026 (zł43.7 Mil).
Biogened's annual market cap
increased
from Dec. 2023 (zł44.2 Mil) to Dec. 2024 (zł56.5 Mil) but then
declined
from Dec. 2024 (zł56.5 Mil) to Dec. 2025 (zł53.0 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Biogened's Enterprise Value for Today is zł61.7 Mil.
Biogened (WAR:BGD) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Biogened Market Cap Related Terms
Biogened Market Cap Historical Data
* Premium members only.
The historical data trend for Biogened's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Biogened's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogened Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biogened's Market Cap distribution charts can be found below:
* The bar in red indicates where Biogened's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Biogened's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biogened (WAR:BGD) has a Market Cap of zł45.0 Mil as of Jul. 08, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Biogened and its competitors. According to the industry distribution chart, Biogened ranks #862 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 84.2%.
Is Biogened's Market Cap too high?
Biogened's current Market Cap is zł45.0 Mil. Based on the distribution chart, Biogened ranks #862 out of 1024 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Biogened has a GF Score™ of 68/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Biogened's Market Cap compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Biogened ranks #862 out of 1024 companies for Market Cap. This places Biogened in the lower half of its industry. The industry median Market Cap is 217.24. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 217.24, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Biogened and its competitors. For the Drug Manufacturers industry, the median Market Cap is 217.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biogened's current Market Cap is zł45.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogened stock overvalued right now?
Based on GuruFocus' analysis, Biogened (WAR:BGD) is currently considered Modestly Undervalued. The stock's GF Value™ is zł23.85, compared to a current price of zł18.30 — trading 23.3% below its estimated fair value. The current Market Cap is zł45.0 Mil. Biogened's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Biogened (WAR:BGD), the current Market Cap is zł45.0 Mil as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biogened (WAR:BGD) Overvalued in 2026?
Based on GuruFocus' analysis, Biogened stock appears to be undervalued.
The current stock price of zł18.30 is trading 23.3% below its estimated GF Value™ of zł23.85.
GuruFocus considers Biogened to be Modestly Undervalued.
Key valuation signals for WAR:BGD:
Market Cap: zł45.0 Mil
GF Value™: zł23.85 vs. price of zł18.30 (23.3% below fair value)
No single metric tells the full story. See the WAR:BGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biogened SA is involved in manufacturing cosmetic and hygiene products. It also designs, produces, and markets safe, effective dermo-cosmetics under the Dermedic brand. The company's products include Dermocosmetics, Thermal water, and Pharmaceutical manufacturing conditions.
68GF Score
Get the complete analysis for WAR:BGD
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:BGD has been successfully added to your 
